Abstract Details
|
Sarah Woodson Smith, MD
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Franck G. Amyot, PhD (HJF) | Dr. Amyot has nothing to disclose. |
| No disclosure on file | |
| Erika Silverman (University of Pennsylvania) | Ms. Silverman has nothing to disclose. |
| Kimbra L. Kenney, MD, FAAN | Dr. Kenney has nothing to disclose. |
| Carol Moore (Henry Jackson Foundation/USUHS) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Ramon R. Diaz-Arrastia, MD, PhD, FAAN (University of Pennsylvania) | Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ischemix, Inc. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pinteon Therapeutics. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from NovaSignal . Dr. Diaz-Arrastia has received stock or an ownership interest from Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense. |